Search
for
Sort by
Research 361–390 of 371
- A Case Series and Literature Review of Telogen Effluvium and Alopecia Universalis after the Administration of a Heterologous COVID-19 Vaccine Scheme
- Immunological Abnormalities In PCOS
- Endocrinology
- Autoimmunity: Alopecia Areata
- Apoptosis resistance in peripheral blood lymphocytes of alopecia areata patients
- Antigen-Specific Regulatory T Cells and Low Dose of IL-2 in Treatment of Type 1 Diabetes
- Volatile organic compounds: A proinflammatory activator in autoimmune diseases
- pMB FLASH - Status and Perspectives of Combining Proton Minibeam with FLASH Radiotherapy
- RETRACTED: Genetic association between asthma and alopecia areata: A two‐sample Mendelian randomization study
- Protein Immobilization on Bacterial Cellulose for Biomedical Application
- Confirmation of Metformin-Induced Acute Generalized Exanthematous Pustulosis Through a Positive Dechallenge-Rechallenge Test: A Case Report and Review of Cutaneous Manifestations Associated With Metformin
- The Cutaneous Side Effects of Selective BRAF Inhibitors and Anti-CTLA4 Agents: the Growing Role of the Dermatologist in the Management of Patients with Metastatic Melanoma
- ODP342 Panhypopituitarism Induced by CTLA-4 and PD-1/PD-L1 Inhibitor Immunotherapy
- Immune-related alopecia (areata and universalis) in cancer patients receiving immune checkpoint inhibitors
- IMMUNE-RELATED SKIN TOXICITIES TO CHECKPOINT INHIBITORS THERAPY
- An In Situ Chemotherapy Drug Combined with Immune Checkpoint Inhibitor for Chemoimmunotherapy
- Dermatologic adverse events associated with chemotherapy and targeted anticancer therapy
- Clinical and Genetic Aspects of Alopecia Areata: A Cutting Edge Review
- Cutaneous Side Effects of Modern Targeted Therapy and Immunotherapy in Patients with Dermatological Malignancies
- The Influence of Flightless I: Regeneration versus Wound Healing
- Taiwanese Dermatological Association consensus on the diagnosis and management of alopecia areata
- BH17 Bridging the gap: identifying dual-targeting therapies for patients with alopecia areata and coexisting immune-mediated inflammatory diseases
- Skin toxicity induced by chemotherapy or molecular targeted therapy combined with immune checkpoint inhibitors in Asian patients: A literature review by the Japanese Pharmacist-led Oncodermatology Study Team
- Safety Profile of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: A Disproportionality Analysis of FDA Adverse Event Reporting System
- Dermatologic Adverse Events from Cancer Treatments
- Alopecia Areata: a Comprehensive Review of Pathogenesis and Management
- Cutaneous manifestations associated with immune checkpoint inhibitors
- Use of oral Janus kinase inhibitors for the treatment of severe alopecia areata: narrative review and real-world experience
- Clinical evidence for JAK inhibition in alopecia areata: A comprehensive review
- Tangled Causes, Targeted Solutions: A Comprehensive Review of Alopecia.